Mayne Pharma Group Ltd. MYX
ASX · Australia · Health Technology
AUD 2.83-0.02 (-0.70%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Mayne Pharma navigates a challenging year with a 411 bps gross margin improvement, driven by DistributeRx momentum and key product wins, despite a 27% drop in underlying EBITDA.
Marquis Who's Who honors Shawn Patrick O'Brien for his expertise in pharmaceuticals and biotechnology. Mr. O'Brien is a seasoned professional in the pharmaceutical industry with over four decades of experience.
It’s looking like we could be in for a green finish to the week with ASX futures tipping a rise of 0.5% for the ASX pre-market after oil prices dipped again overnight and gold travelled back above US$4,500 an ounce. While 'penny stocks' might seem like an outdated term, they continue to offer intriguing possibilities for investors seeking affordable entry points and growth potential. In this article, we highlight three penny stocks that showcase financial strength and resilience, offering...
Mayne Pharma Group Limited CEO Aaron Gray talked with Jonathan Jackson from Proactive at the Small and Mid-Cap Conference about the company’s strategy, product portfolio, and recent H1 results, highlighting its focus on women’s health and dermatology markets in the United States. Gray explained that Mayne Pharma operates across three business units, with two generating all revenue from the US, focused on women’s health and dermatology, while a third international unit covers Australia and other global markets. He emphasized the strength of its women’s health portfolio, which includes four repr
Mayne Pharma Group Ltd (MAYNF) reports strong gross margin improvements and strategic advancements in Women's Health and Dermatology, despite facing competitive and legal challenges.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Aspirin Market size & share revenue was valued at approximately USD 2.52 Billion in 2024 and is expected to reach USD 2.60 Billion in 2025 and is expected to reach around USD 3.40 Billion by 2034, at a CAGR of 3.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bayer AG, Suzhou Kuacai Information Techn
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.